{
  "id": 19816525,
  "title": "Earnings call transcript: PAVmed Q3 2026 loss widens as Lucid gains traction",
  "url": "https://urgent.news/2026/11/13/earnings-call-transcript-pavmed-q3-2026-loss-widens-as-lucid-gains",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T14:13:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-pavmed-q3-2026-loss-widens-as-lucid-gains-traction-93CH-5025685"
  },
  "original_language": "en",
  "account": "PAVmed Inc. reported a preliminary third-quarter net loss of $13.0 million, a significant increase from the $6.0 million loss in the same quarter last year. The company attributes the widening loss to non-cash valuation changes tied to its stake in Lucid Diagnostics, particularly a $10 million decline in the value of Lucid shares. Despite the GAAP loss, PAVmed's non-GAAP net loss improved to $1.2 million from $1.7 million in the previous quarter, suggesting better underlying operating performance. Lucid Diagnostics secured Medicare reimbursement for its EsoGuard, marking a transformational milestone. Veris Health reported nearly doubled monthly enrollment at Ohio State University’s James Cancer Center between July and September. PortIO may pursue a 510(k) regulatory path, potentially shortening the timeline and lowering capital needs. Octeris is making progress toward clinical testing, with a pre-submission package expected and enrollment planned for January 2027. The company's cash balance stands at $8.9 million, with a quarterly burn rate of about $2.8 million. Despite the financial challenges, PAVmed's stock rose 4.56% in premarket trading to $1.40. Analysts forecast 227% revenue growth for fiscal 2026, but the company remains deeply in the pre-commercial stage, with a deeply negative gross profit margin of -221%.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}